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74
75
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77
78Direct-acting antivirals (DAAs) are effective in treatment of hepatitis C virus (HCV) genotype
1 infection, but their cost and value have been debated. We performed a systematic review of
published cost-effectiveness analyses of DAAs, synthesized their results with updated drug
prices, and calculated the maximum price at which DAA therapy for HCV genotype 1 infection is
cost-effective (increased quality-adjusted life-years [QALYs] and increased cost that the society
is willing to pay) and cost-saving (increased QALYs and decreased costs).79
80METHODS:81
82
83
84
85
86
87
88
89We conducted a systematic review of the PubMed, Medline, EMBASE, Cochrane library, EconLit,
Database of Abstracts of Reviews of Effects, National Health Service Economic Evaluation
Database, Health Technology Assessment, and Tufts University databases for cost-effectiveness
analyses published from 2011 through 2015. Our analysis included cost effectiveness of DAAs
versus previous standard-of-care regimens (peginterferon and ribavirin, boceprevir and
telaprevir), or no treatment, performed for patients with HCV genotype 1 infection. We
excluded studies that were not written in English or those that did not report QALYs. Reported
incremental cost-effectiveness ratios (ICERs) and treatment costs for each comparison were
extracted; the threshold price was estimated for each analysis in which regimens were found to
be cost-effective (ICER £$100,000/QALY) or cost-saving (ICER <$0), those that decreased costs
and increased QALYs.90
91RESULTS:92
93
94
95
96
97We identiﬁed 24 cost-effectiveness studies that reported 170 ICERs for combinations of
11 drugs, from 11 countries. Of those, 81 ICERs were determined for ﬁrst-generation DAAs
(boceprevir and telaprevir) and 89 ICERs were determined for second-generation DAAs (drugs
approved after the ﬁrst-generation DAAs) as a primary intervention. The median threshold
prices at which ﬁrst-generation and second-generation DAAs became cost-effective were
estimated as $120,100 (interquartile range, $90,700–$176,800) and $227,200 (interquartile
range, $142,800–$355,800), respectively. At the discounted price of $60,000, a total of 71% of
the analyses found second-generation DAAs to be cost-saving and 22% to be cost-effective.98
99
CONCLUSIONS:100
101In a systematic review, we found treatment of HCV genotype 1 infection with second-generation
DAAs to be cost-effective when they cost less than and $227,200; these drugs produced cost
savings at current discounts.102103
Keywords: Cost Effectiveness; Budget Impact; Public Health; Health Care Expenses.104
105106
107
108
109
110Worldwide, more than 170 million people arechronically infected with hepatitis C virus
(HCV).1 HCV infection is the leading cause of hepatocel-
lular carcinoma and is the most common indication foraper: CEA, cost-effectiveness analysis;
Health Economic Evaluation Reporting
antiviral; HCV, hepatitis C virus; ICER,
ratio; IQR, interquartile range; QALY,
willingness to pay.
LA 5.4.0 DTD  YJCGH54917_proof  1liver transplantation in the United States and Europe.2 Of
the 6 HCV genotypes, genotype 1 is the most prevalent in
the Western world and accounts for at least 70% of all
chronic infections.3© 2016 by the AGA Institute. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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232HCV treatment has rapidly evolved over the past
few years beginning with the launch of 2 direct-acting
antivirals (DAAs), boceprevir and telaprevir, in 2011 for
genotype 1, followed by the availability of several new oral
DAAs from 2013 onward, including sofosbuvir, simepre-
vir, ledipasvir, daclatasvir, and Viekira Pak. New oral
therapies are superior, with efﬁcacy greater than 95% in
most patients, and require shorter duration of treatment
and have fewer adverse effects than the older therapies.
However, the high price coupled with the high
demand for oral DAAs has created concerns about their
impact on health care budgets, delaying timely treatment
to several HCV patients. The high price of these drugs has
led to a national debate about the value and affordability
of HCV treatment in the United States and elsewhere.
Citing these concerns, several payers, including state
Medicaid programs, have restricted these treatments to
patients with advanced stages of hepatic ﬁbrosis.4
Cost-effectiveness analysis (CEA) can inform
stakeholders regarding the value of HCV treatment and
allow them to compare its value with other medical
interventions. Using a decision-analytic modeling approach,
such analysis can project the long-term health beneﬁts of
HCV treatment, predict long-term costs of HCV sequelae,
and weigh them against the cost of up-front treatment.
Several CEAs using models of HCV were recently
published that assessed the value of treatment by
estimating the incremental cost-effectiveness ratios
(ICERs), which provide the cost of gaining 1 additional
quality-adjusted life-year (QALY). However, different
modeling assumptions, including those regarding the
costs of DAAs, may have inﬂuenced their results.
Furthermore, drug prices have come down considerably
after the publication of these cost-effectiveness studies,
so their results are outdated and may not accurately
depict the current real-world value. Our objective was
2-fold: to systematically review the published CEAs of
DAAs and synthesize published results after updating
their cost assumptions, and to estimate the threshold
drug prices below which HCV treatment is cost-effective
and/or cost-saving.
Methods
We synthetized the cost-effectiveness results by
controlling for the drug price, HCV genotype, treatment
history, and geographic region. We followed the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses statement to report our results.
Information Sources and Search
We conducted a literature search in general (ie,
PubMed, Medline, EMBASE, The Cochrane library) and
content-speciﬁc electronic databases (ie, EconLit,
Database of Abstracts of Reviews of Effects, National
Health Service Economic Evaluation Database and HealthFLA 5.4.0 DTD  YJCGH54917_proof  1Technology Assessment database, Tufts CEA registry).
The search covered peer-reviewed original articles pub-
lished from January 1, 2011, until September 8, 2015.
The list of references from potentially relevant articles
was also searched. All results were imported into a
reference manager software and merged, and then
duplicates were removed. Supplementary Table 1 shows
the search strategy used for the Medline database.
Inclusion and Exclusion Criteria
We included any article that reported an economic
model to estimate the cost-effectiveness of treating HCV
patients with DAAs in comparison with old standard of
care, which was dependent on the primary intervention
and the target population. We included all approved DAAs
categorized as ﬁrst-generation and second-generation
DAAs. The ﬁrst-generation DAAs included boceprevir and
telaprevir; and second-generation DAAs included sime-
previr, paritaprevir, asunaprevir, ledipasvir, ombitasvir,
sofosbuvir, daclatasvir, and dasabuvir. The comparators
for ﬁrst-generation DAAs were peginterferon-ribavirin or
no treatment, and the comparators for second-generation
DAAs were ﬁrst-generation DAAs, peginterferon-
ribavirin, or no treatment.
We excluded articles that were not published in
English, not original studies (ie, reviews, opinion articles),
did not provide modeling techniques used, did not report
QALYs, reported only budget impact or cost-of-illness
analysis, did not report any results for genotype 1
patients, reported a drug regimen that has not been
approved by the Food and Drug Administration or
recommended by a professional organization, did not
report cost-effectiveness results compared with the old
standard of care, did not report sensitivity analysis on the
cost of HCV treatment, or only included patients
coinfected with other viral infections (eg, human immu-
nodeﬁciency virus, hepatitis B virus).
Study Selection
Two reviewers screened the titles and abstracts of the
unique citations independently. The ﬁrst step was to
assess whether inclusion criteria were met. Any
disagreements regarding whether or not a particular
analysis fulﬁlled the initial inclusion criteria were
resolved by discussion leading to consensus. We then
retrieved the full text of those relevant citations and
excluded unsuitable analyses according to our exclusion
criteria, resulting in the ﬁnal group of studies analyzed.
Data Collection Process and Data Items
We used a standardized extraction form to collect
information. One reviewer abstracted data from the
included studies and another reviewer crosschecked the
abstracted information. We collected basic information6 November 2016  4:47 pm  ce CJ
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303regarding the study including study year; country for
which the analysis was performed; drug regimen as
primary intervention, which was further categorized as
ﬁrst-generation DAAs (boceprevir- and telaprevir-based
therapies) and second-generation DAAs; and the
comparator regimen. Additional information, such as
characteristics of the modeled population including
presence of cirrhosis, HCV genotype, and treatment
experience, was extracted. Model features relevant to the
cost-effectiveness of HCV treatment, such as perspective,
discount rate, treatment-as-prevention beneﬁts, extra-
hepatic beneﬁts, and reinfection after SVR, were also
noted.304
305
306
307
308
309
310
311
312
313
314
315
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317Quality Appraisal
One investigator (T.H.) assessed the quality of report-
ing using the Consolidated Health Economic Evaluation
Reporting Standards (CHEERS) statement,5 and another
investigator (M.L.-O.) cross-checked the entries. The
CHEERS statement is a 24-item checklist evaluating 6
sections of an economic evaluation. Each of the items was
explicitly judged as follows: Yes¼ “information reported”
or No ¼ “information not reported.” The quality of the
included studies was reported as the number of missing
information across studies per item and converted to
percentages.318
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348Synthesis of Results: Reanalysis of
Incremental Cost-Effectiveness Ratios
and Threshold Drug Price
To account for differences in treatment costs used by
published studies, we recalculated each ICER at the
wholesale acquisition cost of DAAs and over a range of
$20,000–$100,000. We converted all costs to 2014 US
dollar value using the Consumer Price Index for each
country and the average currency conversion rate in
2014.6,7 Because treatment costs and ICERs have a linear
relationship, we used the linear interpolation approach
to ﬁnd the ICER at any treatment cost. For that purpose,
we ﬁrst extracted all reported costs, QALYs, and ICERs
from all studies. For each analysis, we also extracted an
ICER at a different price either using the published 1-way
sensitivity analysis or price-threshold analysis. If the
sensitivity analysis on the cost of HCV treatment was not
reported, we removed that ICER from our analysis. The
following equation provides the ICER (denoted by ICERX)
when the price of DAAs is X:
ICERX ¼

ICERB  ICERA
PriceB  PriceA

 ðX  PriceAÞ þ ICERA
where PriceA and PriceB along with their corresponding
ICERs (ICERA and ICERB) were extracted from the
published studies.FLA 5.4.0 DTD  YJCGH54917_proof  1For each study, we further estimated the threshold
price below which treatment with DAAs would become
cost-effective using the willingness-to-pay (WTP)
threshold of $100,000-per-QALY and cost-saving
(ie, WTP threshold of $0-per-QALY). The following
equation provides the relationship between the
threshold drug price and WTP:
Pricethreshold ¼ PriceA þ ðWTP  ICERAÞ 

PriceB  PriceA
ICERB  ICERA
Results
Our search yielded 304 records. After exclusion of
duplicates and 2-step screening, 24 unique studies were
included in our analysis (Figure 1).Overview of Studies and Patient Characteristics
Twenty-four studies were included in the systematic
review. Supplementary Table 2 provides an overview of
the study characteristics. These studies evaluated
170 ICERs of 11 different drug combinations from 11
different countries (Supplementary Table 3). Among
them, 81 ICERs evaluated ﬁrst-generation DAAs as the
primary intervention; 67 were compared with
peginterferon-ribavirin and 14 with no treatment.
Furthermore, 89 ICERs evaluated second-generation
DAAs as the primary intervention; 67 were compared
with the old standard-of-care (peginterferon-ribavirin or
ﬁrst-generation DAAs) and 22 with no treatment. Table 1
summarizes key modeling features of the included
studies.Region
Among the selected studies, 110 ICERs (65%) were
reported by 10 (42%) studies conducted in the United
States, 51 (26%) ICERs by 12 (44%) studies in Europe, 7
(4%) ICERs by 1 (4%) study in Asia, and 2 (1%) ICERs
by 1 (4%) study in Australia (Supplementary Table 4).Treatment Strategies
The cost-effectiveness models evaluated the following
DAAs as primary interventions: ﬁrst-generation DAAs
boceprevir or telaprevir, in combination with peginter-
feron and ribavirin; and second-generation DAAs con-
sisting of sofosbuvir and/or simeprevir with
peginterferon and ribavirin, and oral DAAs consisting of
different combinations of sofosbuvir, ledipasvir, dacla-
tasvir with or without ribavirin, and ombitasvir/par-
itaprevir/ritonavir with dasabuvir and/or ribavirin
(Figure 2).6 November 2016  4:47 pm  ce CJ
Q8
Q9
Figure 1. Flow chart of study selection process. COS; FDA, Food and Drug Administration; HIV, human immunodeﬁciency
virus; TEL, telaprevir. Q12
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464Modeling Assumptions
We noted structural assumptions made by published
studies that are important in the context of HCV modeling
and could impact the cost-effectiveness results. With the
exception of 1 study,8 which used a societal perspective,
all other studies used the payer’s perspective. We found
that none of the studies captured the beneﬁts of HCV
treatment in reducing HCV transmission (ie, treatment as
prevention); no study considered extrahepatic beneﬁts
associated with HCV treatment; only 1 study considered
indirect economic beneﬁts resulting from HCV cure8; and
only 4 out of 24 studies8–13 modeled the possibility of
reinfection after achieving SVR.
Quality of Reporting
Supplementary Figure 1 summarizes the percentage
of studies adequately reporting (and not reporting) each
CHEERS methodologic item evaluated. In 29% of the
studies an adequate structured abstract according to
CHEERS standards was not provided, 20% did notFLA 5.4.0 DTD  YJCGH54917_proof  1adequately describe target population and subgroups,
and 54% did not adequately describe the population and
methods used to elicit preferences for outcomes. In
addition, 17% did not provide the methodologic
approach used to estimate resource use, and 29% did not
explore all characteristics of uncertainty associated with
patient-level data or model parameters.Incremental Cost-Effectiveness Ratios
We estimated the ICER of each reported analysis by
varying the price of DAAs from $20,000 to $100,000 and
summarized the results by plotting the percentage of
analyses that would be cost-saving, cost-effective, and
not cost-effective for a given drug price. Figure 3A shows
the results of 81 ICERs reported for ﬁrst-generation
DAAs. For instance, at a $60,000 price for DAAs, 2%
analyses found ﬁrst-generation DAAs to be cost-saving,
91% were found to be cost-effective, and 7% were
found to be not cost-effective. Similarly, Figure 3B sum-
marizes the results of 89 ICERs reported for second-
generation DAAs. At a $60,000 price for these DAAs,6 November 2016  4:47 pm  ce CJ
Table 1. Summary of Modeling Features of Included Studies
Author, year, country Prior treatment Drug regimens evaluated
Time
horizon Perspective
Discount
rate (cost,
QALY), %
TasP
beneﬁt
Extrahepatic
beneﬁts
Indirect
economic
beneﬁts
Reinfection
after
SVR
Sponsor
type
Camma et al, 201219,
Italy
Naive BOC- and TEL-based
therapies compared
with PEG-RBV
20 y Payer 3, 3 No No No No Nonproﬁt
center
Liu et al, 201220,
United States
Naive BOC- and TEL-based
therapies compared
with PEG-RBV
Life-long Payer 3, 3 No No No No Nonproﬁt
center
Camma et al, 201321,
Italy
Experienced BOC- and TEL-based
therapies compared
with PEG-RBV
Life-long Payer 3, 3 No No No No Nonproﬁt
center
Chhatwal et al, 201322,
United States
Experienced BOC-based therapies
compared with PEG-RBV
Life-long Payer 3, 3 No No No No Pharma
Elbasha et al, 201323,
Portugal
Naive,
experienced
BOC-based therapies
compared with PEG-RBV
Life-long Payer 3, 3 No No No No Pharma
Ferrante et al, 201324,
United States
Naive BOC-based therapies
compared with PEG-RBV
Life-long Payer 3, 3 No No No No Pharma
Brogan et al, 201425,
United States
Naive,
experienced
TEL-based therapies
compared with PEG-RBV
Life-long Payer 3, 3 No No No No Pharma
Cure et al, 201426,
United Kingdom
Experienced BOC- and TEL-based
therapies compared
with PEG-RBV
Life-long Payer 3.5, 3.5 No No No No Pharma
Cure et al, 201427,
United Kingdom
Naive BOC- and TEL-based
therapies compared
with PEG-RBV
Life-long Payer 3.5, 3.5 No No No No Pharma
Dan et al, 201428,
Singapore
Naive,
experienced
BOC-based therapies
compared with
PEG-RBV
Life-long Payer 3, 3 No No No No Pharma
Liu et al, 20149,
United States
Naive SOF-based therapies,
BOC-based therapies,
PEG-RBV, and no treatment
Life-long Payer 3, 3 No No No Yes Government
Petta et al, 201429,
Italy
Naive SOF-based therapies
compared with BOC-
and TEL-based therapies
Life-long Payer 3, 3 No No No No Nonproﬁt
center
Saab et al, 201430,
United States
Naive,
experienced
SOF-based therapies
compared with SMV-, BOC-,
and TEL-based therapies,
and PEG-RBV
Life-long Payer 3, 3 No No No No Pharma
Vellopoulou et al, 20148,
The Netherlands
Naive,
experienced
BOC- and TEL-based
therapies compared
with PEG-RBV
Life-long Societal 4, 1.5 No No Yes Yes Pharma
Warren et al, 201431,
Australia
Naive,
experienced
TEL-based therapies
compared with PEG-RBV
60 y
(life-long)
Payer 5, 5 No No No No Pharma
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Table 1. Continued
Author, year, country Prior treatment Drug regimens evaluated
Time
horizon Perspective
Discount
rate (cost,
QALY), %
TasP
beneﬁt
Extrah patic
ben ﬁts
Indirect
economic
beneﬁts
Reinfection
after
SVR
Sponsor
type
Chhatwal et al, 201532,
United States
Naive,
experienced
SOF-based therapies
compared with BOC- and
TEL-based therapies,
and PEG-RBV
Life-long Payer 3, 3 No N No No Government
Najafzadeh et al, 201533,
United States
Naive SOF/LDV, SOF/DCV,
and SOF/RBV
compared with PEG/RBV
Life-long Payer 3, 3 No N No No Insurance
Younossi et al, 201534,
United States
Naive,
experienced
SOF/LDV compared
with other available therapies
Life-long Payer 3, 3 No N No No Pharma
Athanasakis et al, 201535,
Greece
Naive,
experienced
BOC-based therapies
compared with PEG-RBV
Life-long Payer 3, 3 No N No No Pharma
Pfeil et al, 201511,
Switzerland
Naive,
experienced
SOF-based therapies
compared with BOC- and
TEL-based therapies,
PEG-RBV, and no treatment
Life-long Payer 3, 3 No N No Yes Pharma
Zhang et al, 201512,
United States
Naive SOF-based therapies
compared with PEG-RBV
on G2 patients; CEA of
SOF/LDV, SOF/SMV,
SOF/PEG-RBV, Viekira Pak,
and TEL-based therapies
Life-long Payer 3, 3 No N No Yes None Q11
Westerhout et al, 201536,
United Kingdom
Naive,
experienced
SMV-based therapies
compared with PEG-RBV
Life-long Payer 3.5, 3.5 No N No No Pharma
Odhiambo et al, 201337,
Hungary
Naive,
experienced
BOC-based therapies
compared with PEG-RBV
Life-long Payer 5, 5 No N No No None
Gimeno-Ballester
et al, 201538,
Spain
Naive SOF/DCV therapies
compared with BOC-
and TEL-based therapies
Life-long Payer 3, 3 No N No No None
BOC, boceprevir; DCV, daclatasvir; LDV, ledipasvir; PEG, peginterferon; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir; SVR; TasP, treatment-as-prevention; L, telaprevir; Viekira Pak, a combination of ombitasvir,
paritaprevir, ritonavir, and dasabuvir.
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Figure 2. Counts of drug
regimens evaluated as
primary intervention. BOC,
boceprevir; DCV, dacla-
tasvir; LDV, ledipasvir;
PEG, peginterferon; RBV,
ribavirin; SMV, simeprevir;
SOF, sofosbuvir; TEL,
telaprevir. Other category
evaluated: SMV-DCV and
Viekira Pak þ RBV.
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Figure 3. (A) Summary of
81 ICERs reported for
ﬁrst-generation DAAs
when compared with the
old standard of care
(peginterferon-ribavirin or
no treatment). (B) Summary
of 89 ICERs reported for
second-generation DAAs
when compared with
the old standard of care
(ﬁrst-generation DAAs,
peginterferon-ribavirin, or
no treatment).
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88771% of the analyses found them to be cost-saving, 22%
found them cost-effective, and 7% of the analyses found
them not cost-effective.
We further conducted a subgroup analysis of second-
generation DAAs. The cost-effectiveness of DAAs was
similar in treatment-naive versus -experienced patients
(Figure 4A and B) and patients with cirrhosis versus
patients without cirrhosis (Figure 4C and D). However,
results differed substantially in US versus non-US-based
analyses (Figure 4E and F). All of the analyses that found
HCV treatment not cost-effective evaluated a combina-
tion of simeprevir-sofosbuvir-ribavirin.
Threshold Drug Price
The price thresholds at which DAA regimens become
cost-effective and cost-saving were substantially lowerFigure 4. Summary of ICERs of second-generation DAAs com
peginterferon-ribavirin, or no treatment) in (A) treatment-naive
patients with cirrhosis, (D) patients without cirrhosis, (E) U.S. st
FLA 5.4.0 DTD  YJCGH54917_proof  1for ﬁrst-generation therapies compared with second-
generation therapies (Figure 5). The median threshold
price of the treatment at which ﬁrst-generation and
second-generation DAAs become cost-effective compared
with the old standard-of-care was $120,100 (inter-
quartile range [IQR], $90,700–$176,800) and $227,200
(IQR, $142,800–$335,900), respectively. The corre-
sponding threshold price for DAAs to become cost-saving
were $11,700 (IQR, $2,200–$19,300) and $70,900 (IQR,
$43,300–$103,700), respectively.
We further conducted a subgroup analysis on second-
generation DAAs (Supplementary Figure 2A–C). The
media drug price of DAAs used in US and non-US studies
was $84,000 and $55,800, respectively. The median
threshold price of the treatment at which these DAAs
become cost-effective was above $200,000 irrespective
of patients’ prior treatment history or presence ofpared with the old standard of care (ﬁrst-generation DAAs,
patients (TN), (B) treatment-experienced patients (TE), (C)
udies, and (F) non-U.S. studies.
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Figure 5. Box plots showing the median, 25th percentile,
and 75th percentile price threshold analyses below
which treatment with DAAs is cost-effective (using
$100,000-per-QALY willingness-to-pay threshold) and
cost-saving.
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1044cirrhosis. Similarly, the threshold price of treatment at
which DAAs become cost-saving was around $70,000
irrespective of patients’ prior treatment history or
presence of cirrhosis. However, the price thresholds
were substantially different for US versus non-US
studies. The median threshold price for DAA regimens
to become cost-effective was $260,300 (IQR,
$183,800–$369,600) in US studies and $161,000 (IQR,
$0–$219,600) in non-US studies. The corresponding
price at which they become cost-saving was $79,000
(IQR, $60,300–$110,000) in US studies in contrast to
$15,000 (IQR, $0–$31,200) in non-US studies.
Sensitivity Analysis Using $50,000
Willingness-to-Pay Threshold
We also conducted a sensitivity analysis using
a conservative WTP threshold of $50,000-per-QALY.
We found that the median threshold price of DAA
regimens to become cost-effective in ﬁrst-generation
and second-generation drugs decreased to $66,800
(IQR, $44,900–$100,500) and $156,600 (IQR,
$98,700–$228,100), respectively. The corresponding
threshold prices in US and non-US analyses were
$167,200 (IQR, $114,300–$232,000) and $94,800 (IQR,
$0–$114,900), respectively, which still remainedFLA 5.4.0 DTD  YJCGH54917_proof  1substantially below the listed wholesale acquisition
cost of the DAAs.Discussion
The recent availability of DAAs is expected to
dramatically impact the landscape of HCV burden.14,15
However, the cost of DAAs and the large number of
patients with HCV infection have become a barrier to
provision of timely treatment. Although the effective
prices of oral DAAs have fallen substantially since their
launch in late 2013, the results of published cost-
effectiveness models have not been updated to accu-
rately estimate the current value of HCV treatment. To
address this crucial but missing gap in evidence, we
systematically analyzed the results of 24 studies of HCV
genotype 1 presenting 170 ICERs of combinations of 11
drugs from 11 countries. We found that most of the
modeling studies concluded that oral DAAs provide good
value for money, and can also result in substantial eco-
nomic savings at current discounts.
To our knowledge, our study is the ﬁrst to synthesize
the results of the published cost-effectiveness studies of
HCV treatment in the era of DAAs. Previous studies limited
their scope to the systematic review of modeling
approaches of HCV models and did not evaluate or
reanalyze the cost-effectiveness results.16,17Moreover, we
used a novel approach to present the cost-effectiveness
results by providing the percent of studies per ICER and
controlling for the drug price, patient’s HCV genotype,
prior treatment history, disease severity, and the region of
the analysis. The evidence from our study that included 24
modeling studies is stronger than the evidence from any
individual CEA study.
Our study has some limitations, therefore our results
should be interpreted with caution. First, our synthesis is
limited by the reported information in the included
studies. For this reason, we evaluated their quality of
reporting using the CHEERS statement and found that
most items were adequately reported with only 1 poorly
reported area (methods used to derive preferences for
outcomes) in half of the studies. Second, our results
could not control for several other model inputs
including quality of life weights, discount rate, and cost
of health states, which could lead to heterogeneity in
results. Third, the focus of our study was on the cost-
effectiveness of HCV treatment using DAAs, so our
analysis did not include modeling studies that evaluated
the cost-effectiveness of HCV screening plus treatment.
We observed that US-based studies found HCV treat-
ments to be more cost-effective than non-US-based
studies despite the fact that the price of DAAs was
higher in the United States than outside the United States.
The reason for such trend could be that the cost of man-
aging HCV-associated sequelae is higher in the United
States; therefore, the economic beneﬁts of preventing
advanced sequelae were higher in the United States.6 November 2016  4:47 pm  ce CJ
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1139We believe that the published modeling studies could
have underestimated the value of HCV treatment because
most studies did not consider the beneﬁts of HCV
treatment in preventing transmission, extrahepatic ben-
eﬁts resulting from HCV treatment, such as in reduction
in the incidence of non-Hodgkin lymphoma.18 Therefore,
future modeling studies should consider the previously
mentioned factors to evaluate a more precise value of
HCV treatment with DAAs.
Our study reinforces the message that the widespread
and unrestricted treatment of HCV is the optimal strategy
from apublic health and economic perspective. There is an
unprecedented situation with the availability of DAAs,
which are potentially cost-saving interventions but the
upfront (or initial) budget impact to implement these
interventions is large. Our study provides evidence
suggesting that HCV treatment can result in cost-savings.
To our knowledge, not many treatments have been
shown to be cost-saving in the history of medicine. Hence,
we would support additional resources allocated to
increased access to HCV treatment, as has been the case
with human immunodeﬁciency virus.
In conclusion, our systematic reanalysis of cost-
effectiveness studies found that HCV treatment with
second-generation DAAs is highly cost-effective and could
likely result in cost-savings at currently available
discounts. Therefore, timely treatment with DAAs without
restrictions for HCV should be a priority to improve public
health.
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Supplementary Figure 1. Summary of the reported items according to CHEERS checklist.
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Supplementary Figure 2. Box plots showing the median threshold price, 25th quartile, and 75th quartile at which treatment
with second-generation DAAs is cost-effective (using $100,000-per-QALY willingness-to-pay threshold) and cost-saving in (A)
treatment-naive versus treatment-experienced patients, (B) patients with versus without cirrhosis, and (C) and US versus non-
US studies.
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Supplementary Table 1.Medline Search Strategy
# Searches
1 exp HEPATITIS C/
2 exp HEPACIVIRUS/
3 ((hepatitis adj3 “C”) or hepacivir* or HCV).ti,ab.
4 or/1-3
5 (telaprevir* or Incivek*).mp.
6 (boceprevir* or Victrelis*).mp.
7 (simeprevir* or Olysio* or TMC-435* or TMC435*
or TMC-435350* or TMC435350*).mp.
8 (paritaprevir* or Veruprevir*).mp.
9 (asunaprevir* or BMS-650032* or BMS650032*).mp.
10 (ledipasvir* or GS-5885* or GS5885*).mp.
11 (ombitasvir* or ABT-267* or ABT267*).mp.
12 (sofosbuvir* or Sovaldi* or GS-7977* or GS7977*
or PSI-7977* or PSI7977*).mp.
13 (dasabuvir* or ABT-333* or ABT333*).mp.
14 (daclatasvir* or Daklinza*).mp.
15 exp PROTEASE INHIBITORS/
16 (protease* adj3 inhibit*).mp.
17 (direct* adj3 (anti-viral* or antiviral*)).mp.
18 exp ANTIVIRAL AGENTS/ and (direct* adj3
(act or acting)).ti,ab.
19 or/5-18
20 4 and 19
21 limit 20 to English language
22 limit 21 to yr¼“2011 -Current”
23 limit 22 to “review”
24 22 not 23
25 exp HEPATITIS C/ec
26 exp ANTIVIRAL AGENTS/ec
27 exp PROTEASE INHIBITORS/ec
28 exp MODELS, ECONOMIC/
29 exp ECONOMICS/
30 (cost or costs or costing or economi* or budget* or ﬁnanc*
or pharmacoeconom* or pharmacoeconom* or price*
or pricing or expenditure* or affordab* or fee or fees
or charg* or monetar*).ti,hw,kw.
31 (economic* adj2 (burden* or barrier* or restriction* or
resources)).ab.
32 ((cost or costs) adj3 (utilit* or effectiv* or beneﬁt* or
minimiz* or minimis* or model*)).ab.
33 ((decision* or cost*) adj3 (model* or analy*)).ti,ab,sh.
34 or/25-33
35 24 and 34
NOTE. Databases include Ovid MEDLINE(R) In-Process & Other Non-Indexed
Citations and Ovid MEDLINE(R). Searched on September 9, 2015.
Supplementary Table 2. Summary of Study and Patient
Characteristics
Studies
First-generation
DAAs
Second-generation
DAAs
Number
of ICERs
Number
of studies
Number
of ICERs
Number
of studies
All studies 81 18 89 10
By treatment history
Treatment naive 40 15 66 10
Treatment
experienced
41 12 23 4
By cirrhosis
Noncirrhosis only 12 6 27 6
Cirrhosis only 8 4 25 5
Mixeda 61 17 37 8
By region
United States 36 6 74 6
Non-United States 45 12 15 4
aMixed implies that results included patients with and without cirrhosis.
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Supplementary Table 3. Cost-Effectiveness Results Extracted From Each Study and Analysis of the Results Q13
Number Study Country
Treatment
history
Fibrosis
stage
IFN
tolerance
Primary
intervention Comparator
Reported
ICER
ICER at
$60,000
Threshold
drug price
($100,000 ICER)
Threshold
drug price
($0 ICER)
1 Camma et al, 201222 Italy TN Noncirrhosis Yes BOC-PEG-RBV PEG-RBV $9835 $23,204 $222,808 $10,808
2 Italy TN Noncirrhosis Yes TEL-PEG-RBV PEG-RBV $14,194 $17,762 $296,845 $8845
3 Liu et al, 201223 United States TN Noncirrhosis Yes BOC-PEG-RBV PEG-RBV $67,891 $170,642 $36,688 $3688
4 United States TN Mix Yes BOC-PEG-RBV PEG-RBV $35,670 $86,279 $69,193 $2193
5 United States TN Noncirrhosis Yes TEL-PEG-RBV PEG-RBV $89,490 $112,469 $54,140 $7140
6 United States TN Mix Yes TEL-PEG-RBV PEG-RBV $46,973 $58,463 $99,045 $5045
7 Camma et al, 201324 Italy TE Mix Yes BOC-PEG-RBV No treatment $7140 $13,824 $442,623 < $0
8 Italy TE Mix Yes TEL-PEG-RBV No treatment $5964 $13,385 $501,737 < $0
9 Italy TE Mix Yes BOC-PEG-RBV No treatment $8793 $18,067 $322,184 $2184
10 Italy TE Mix Yes TEL-PEG-RBV No treatment $11,049 $18,505 $352,566 < $0
11 Italy TE Mix Yes TEL-PEG-RBV No treatment $19,281 $32,027 $202,743 < $0
12 Chhatwal et al, 201325 United States TE Mix Yes BOC-PEG-RBV PEG-RBV $28,939 $66,098 $90,173 $1173
13 United States TE Mix Yes BOC-PEG-RBV PEG-RBV $33,489 $75,788 $78,643 $1643
14 United States TE Mix Yes BOC-PEG-RBV PEG-RBV $33,436 $72,072 $84,576 < $0
15 United States TE Noncirrhosis Yes BOC-PEG-RBV PEG-RBV $35,173 $73,728 $80,755 $1755
16 United States TE Cirrhosis Yes BOC-PEG-RBV PEG-RBV $10,055 $15,566 $329,346 $10,346
17 United States TE Mix Yes TEL-PEG-RBV PEG-RBV $14,087 $19,712 $214,154 $22,154
18 United States TE Mix Yes TEL-PEG-RBV PEG-RBV $30,274 $37,774 $149,606 $5606
19 United States TE Mix Yes TEL-PEG-RBV PEG-RBV $66,822 $80,492 $75,411 < $0
20 Elbasha et al, 201326 Portugal TN Mix Yes BOC-PEG-RBV PEG-RBV $14,854 $76,662 $75,870 $7870
21 Portugal TE Mix Yes BOC-PEG-RBV PEG-RBV $11,240 $41,204 $131,731 $9731
22 Ferrante et al, 201327 United States TN Mix Yes BOC-PEG-RBV PEG-RBV $14,072 $71,761 $77,508 $15,508
23 United States TN Mix Yes BOC-PEG-RBV PEG-RBV $54,891 $90,981 $65,863 $863
24 Brogan et al, 201428 United States TN Mix Yes TEL-PEG-RBV PEG-RBV $16,311 $15,919 $160,898 $40,898
25 United States TE Mix Yes TEL-PEG-RBV PEG-RBV -$4099 -$4273 $341,538 $71,538
26 United States TE Mix Yes TEL-PEG-RBV PEG-RBV $23,565 $23,251 $175,123 $25,123
27 United States TE Mix Yes TEL-PEG-RBV PEG-RBV $32,204 $31,812 $141,826 $21,826
28 Cure et al, 201429 United Kingdom TE Mix Yes TEL-PEG-RBV PEG-RBV $3170 $19,964 $178,453 $30,453
29 United Kingdom TE Mix Yes TEL-PEG-RBV PEG-RBV $10,962 $36,083 $127,752 $21,752
30 United Kingdom TE Mix Yes TEL-PEG-RBV PEG-RBV $32,049 $77,181 $73,463 $14,463
31 United Kingdom TE Mix Yes BOC-PEG-RBV PEG-RBV $28,412 $46,306 $112,083 $15,083
32 United Kingdom TE Mix Yes BOC-PEG-RBV PEG-RBV $20,460 $35,295 $135,705 $18,705
33 Cure et al, 201430 United Kingdom TN Noncirrhosis Yes TEL-PEG-RBV PEG-RBV $21,955 $55,764 $97,159 $13,159
34 United Kingdom TN Cirrhosis Yes TEL-PEG-RBV PEG-RBV $13,944 $46,966 $105,609 $19,609
35 United Kingdom TN Mix Yes TEL-PEG-RBV PEG-RBV $19,215 $52,238 $101,075 $15,075
36 United Kingdom TN Mix Yes BOC-PEG-RBV PEG-RBV $32,626 $78,755 $73,809 $8809
37 Dan et al, 201431 Singapore TN Mix Yes BOC-PEG-RBV PEG-RBV $135 $35,874 $108,237 $20,237
38 Singapore TE Mix Yes BOC-PEG-RBV PEG-RBV -$1493 $14,512 $174,054 $31,054
39 Singapore TN Noncirrhosis Yes BOC-PEG-RBV PEG-RBV -$988 $33,572 $112,255 $21,255
40 Singapore TN Cirrhosis Yes BOC-PEG-RBV PEG-RBV $114,559 $299,558 $17,881 $881
41 Singapore TE Noncirrhosis Yes BOC-PEG-RBV PEG-RBV $961 $22,350 $134,891 $27,891
42 Singapore TE Cirrhosis Yes BOC-PEG-RBV PEG-RBV -$6009 -$110 $440,234 $52,234
43 Singapore TE Mix Yes BOC-PEG-RBV PEG-RBV $4098 $34,338 $120,094 $16,094
F
L
A
5
.4
.0
D
T
D

Y
JC
G
H
5
4
91
7
_
p
ro
o
f

1
6
N
o
v
em
b
er
2
0
1
6

4
:4
7
p
m

ce
C
J
11.e3
C
hhatw
al
et
al
C
linical
G
astroenterology
and
H
epatology
V
ol.
-
,
N
o.
-
1
5
0
9
1
5
1
0
1
5
1
1
1
5
1
2
1
5
1
3
1
5
1
4
1
5
1
5
1
5
1
6
1
5
1
7
1
5
1
8
1
5
1
9
1
5
2
0
1
5
2
1
1
5
2
2
1
5
2
3
1
5
2
4
1
5
2
5
1
5
2
6
1
5
2
7
1
5
2
8
1
5
2
9
1
5
3
0
1
5
3
1
1
5
3
2
1
5
3
3
1
5
3
4
1
5
3
5
1
5
3
6
1
5
3
7
1
5
3
8
1
5
3
9
1
5
4
0
1
5
4
1
1
5
4
2
1
5
4
3
1
5
4
4
1
5
4
5
1
5
4
6
1
5
4
7
1
5
4
8
1
5
4
9
1
5
5
0
1
5
5
1
1
5
5
2
1
5
5
3
1
5
5
4
1
5
5
5
1
5
5
6
1
5
5
7
1
5
5
8
1
5
5
9
1
5
6
0
1
5
6
1
1
5
6
2
1
5
6
3
1
5
6
4
1
5
6
5
1
5
6
6
1
5
6
7
1
5
6
8
1
5
6
9
1
5
7
0
1
5
7
1
1
5
7
2
1
5
7
3
1
5
7
4
1
5
7
5
1
5
7
6
1
5
7
7
1
5
7
8
1
5
7
9
1
5
8
0
1
5
8
1
1
5
8
2
1
5
8
3
1
5
8
4
1
5
8
5
1
5
8
6
1
5
8
7
1
5
8
8
1
5
8
9
1
5
9
0
1
5
9
1
1
5
9
2
1
5
9
3
1
5
9
4
1
5
9
5
1
5
9
6
1
5
9
7
1
5
9
8
1
5
9
9
1
6
0
0
1
6
0
1
1
6
0
2
1
6
0
3
1
6
0
4
1
6
0
5
1
6
0
6
1
6
0
7
1
6
0
8
1
6
0
9
1
6
1
0
1
6
1
1
1
6
1
2
1
6
1
3
1
6
1
4
1
6
1
5
1
6
1
6
1
6
1
7
1
6
1
8
1
6
1
9
1
6
2
0
1
6
2
1
1
6
2
2
1
6
2
3
1
6
2
4
44 Liu et al, 201412 United States TN Mix Yes SOF-PEG-RBV No treatment $28,877 $31,906 $200,274 < $0
45 United States TN Mix Yes SOF-PEG-RBV PEG-RBV $8179 $12,055 $201,591 $40,591
46 United States TN Mix Yes BOC-PEG-RBV No treatment $40,627 $67,582 $102,467 < $0
47 United States TN Mix Yes BOC-PEG-RBV PEG-RBV $8028 $49,088 $103,784 $17,784
48 United States TN Mix Yes SOF-PEG-RBV BOC-PEG-RBV $8353 $16,673 $180,866 $42,175
49 Petta et al, 201432 Italy TN Mix Yes SOF-PEG-RBV BOC-PEG-RBV $15,772 $19,454 $232,059 $22,842
50 Italy TN Mix Yes SOF-PEG-RBV TEL-PEG-RBV $19,482 $25,182 $181,078 $25,537
51 Italy TN Noncirrhosis Yes SOF-PEG-RBV BOC-PEG-RBV $16,409 $19,491 $264,777 $14,826
52 Italy TN Noncirrhosis Yes SOF-PEG-RBV TEL-PEG-RBV $25,407 $31,617 $162,326 $19,569
53 Italy TN Cirrhosis Yes SOF-PEG-RBV BOC-PEG-RBV $4132 $6142 $423,260 $40,003
54 Italy TN Cirrhosis Yes SOF-PEG-RBV TEL-PEG-RBV $27,488 $37,395 $120,729 $31,240
55 Saab et al, 201433 United States TN Noncirrhosis Yes BOC-PEG-RBV No treatment $7757 $27,751 $169,096 $18,096
56 United States TN Cirrhosis Yes BOC-PEG-RBV No treatment $21,623 $32,561 $246,131 < $0
57 United States TN Cirrhosis Yes BOC-PEG-RBV PEG-RBV $25,168 $52,366 $112,873 $1873
58 United States TN Cirrhosis Yes TEL-PEG-RBV No treatment $23,297 $28,483 $282,417 < $0
59 United States TN Cirrhosis Yes TEL-PEG-RBV PEG-RBV $27,884 $38,932 $149,159 $3159
60 United States TN Cirrhosis Yes SOF-PEG-RBV BOC-PEG-RBV $7632 -$11,266 $265,838 $68,976
61 United States TN Cirrhosis Yes SMV-PEG-RBV BOC-PEG-RBV $60,815 $14,661 $75,290 $51,582
62 United States TN Cirrhosis Yes SOF-PEG-RBV TEL-PEG-RBV -$3349 -$29,436 $283,024 $90,450
63 United States TN Cirrhosis Yes SMV-PEG-RBV TEL-PEG-RBV $22,127 $1,000,000a $0a $0a
64 United States TN Mix Yes BOC-PEG-RBV No treatment $11,552 $29,104 $181,941 $9941
65 United States TN Noncirrhosis Yes BOC-PEG-RBV PEG-RBV $254,296 $505,879 $11,295 < $0
66 United States TN Mix Yes BOC-PEG-RBV PEG-RBV $107,421 $215,242 $27,732 < $0
67 United States TN Mix Yes TEL-PEG-RBV No treatment $12,793 $20,818 $219,157 $18,157
68 United States TN Mix Yes TEL-PEG-RBV PEG-RBV $63,021 $91,319 $64,948 $7948
69 United States TN Mix Yes SOF-PEG-RBV BOC-PEG-RBV -$7089 -$36,358 $220,119 $93,011
70 United States TN Mix Yes SMV-PEG-RBV BOC-PEG-RBV -$8430 -$27,180 $129,278 $70,919
71 United States TN Mix Yes SOF-PEG-RBV TEL-PEG-RBV -$21,995 -$67,278 $219,341 $108,402
72 United States TN Mix Yes SMV-PEG-RBV TEL-PEG-RBV -$284,726 -$484,726 $100,422 $91,475
73 United States TE Mix Yes BOC-PEG-RBV No treatment $49,271 $66,575 $94,093 < $0
74 United States TE Mix Yes BOC-PEG-RBV PEG-RBV $31,168 $56,027 $91,221 $20,221
75 United States TN Noncirrhosis Yes TEL-PEG-RBV No treatment $9067 $18,129 $205,731 $27,731
76 United States TE Mix Yes TEL-PEG-RBV No treatment $39,675 $50,611 $121,737 < $0
77 United States TE Mix Yes TEL-PEG-RBV PEG-RBV $22,836 $37,378 $118,864 $24,864
78 United States TE Mix Yes SOF-PEG-RBV BOC-PEG-RBV -$19,350 -$44,350 $315,079 $121,465
79 United States TE Mix Yes SMV-PEG-RBV BOC-PEG-RBV $3586 -$8659 $197,841 $61,096
80 United States TE Mix Yes SOF-PEG-RBV TEL-PEG-RBV -$24,539 -$57,415 $286,726 $123,944
81 United States TE Mix Yes SMV-PEG-RBV TEL-PEG-RBV $9309 -$13,767 $145,118 $57,878
82 United States TN Noncirrhosis Yes TEL-PEG-RBV PEG-RBV $89,591 $130,950 $47,929 $8929
83 United States TN Noncirrhosis Yes SOF-PEG-RBV BOC-PEG-RBV -$12,484 -$45,817 $209,540 $97,933
84 United States TN Noncirrhosis Yes SMV-PEG-RBV BOC-PEG-RBV -$13,525 -$30,192 $140,533 $74,880
85 United States TN Noncirrhosis Yes SOF-PEG-RBV TEL-PEG-RBV -$29,808 -$83,141 $206,271 $112,077
86 United States TN Noncirrhosis Yes SMV-PEG-RBV TEL-PEG-RBV -$103,270 -$169,937 $120,561 $93,719
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Supplementary Table 3. Continued
Number Study Country
Treatment
history
Fibrosis
stage
IFN
tolerance
Primary
intervention Comparator
Reported
ICER
ICER at
$60,000
Threshold
drug price
($100,000 ICER)
Threshold
drug price
($0 ICER)
87 Vellopoulou et al, 201411 The Netherlands TN Mix Yes BOC-PEG-RBV PEG-RBV $9390 $51,674 $101,077 $16,077
88 The Netherlands TN Mix Yes TEL-PEG-RBV PEG-RBV -$445 $24,495 $144,566 $32,566
89 The Netherlands TE Mix Yes BOC-PEG-RBV PEG-RBV $15,519 $54,586 $101,781 $9,781
90 The Netherlands TE Mix Yes TEL-PEG-RBV PEG-RBV -$6532 $10,604 $205,715 $42,715
91 The Netherlands TE Mix Yes BOC-PEG-RBV PEG-RBV $3729 $30,352 $154,025 $19,025
92 The Netherlands TE Mix Yes TEL-PEG-RBV PEG-RBV -$9131 $5570 $239,416 $49,416
93 The Netherlands TE Mix Yes BOC-PEG-RBV PEG-RBV $3729 $30,352 $154,025 $19,025
94 The Netherlands TE Mix Yes TEL-PEG-RBV PEG-RBV -$9131 $5570 $239,416 $49,416
95 Warren et al, 201434 Australia TN Mix Yes TEL-PEG-RBV PEG-RBV $26,499 $52,640 $98,835 $16,835
96 Australia TE Mix Yes TEL-PEG-RBV PEG-RBV $20,704 $38,120 $138,588 $11,588
97 Chhatwal et al, 201535 United States TN Noncirrhosis Yes SOF-LDV BOC-PEG-RBV $25,069 -$1571 $108,760 $54,530
98 United States TE Cirrhosis Yes SOF-LDV TEL-PEG-RBV $79,205 -$28,146 $197,139 $58,022
99 United States TN Noncirrhosis Yes SOF-LDV TEL-PEG-RBV $25,069 -$1571 $132,315 $46,650
100 United States TN Noncirrhosis No SOF-LDV No treatment $39,636 $32,644 $138,268 $22,068
101 United States TN Cirrhosis Yes SOF-LDV BOC-PEG-RBV $5344 -$20,800 $259,895 $74,181
102 United States TN Cirrhosis Yes SOF-LDV TEL-PEG-RBV $5344 -$20,800 $278,416 $73,135
103 United States TN Cirrhosis No SOF-LDV No treatment $17,974 $7799 $278,424 $41,524
104 United States TE Noncirrhosis Yes SOF-LDV BOC-PEG-RBV $35,801 -$29,880 $120,602 $63,752
105 United States TE Noncirrhosis Yes SOF-LDV BOC-PEG-RBV $35,801 -$29,880 $133,356 $56,640
106 United States TE Cirrhosis Yes SOF-LDV BOC-PEG-RBV $79,205 -$28,146 $196,224 $61,506
107 Najafzadeh et al, 201536 United States TN Mix Yes SOF-PEG-RBV BOC-PEG-RBV $21,673 -$4701 $194,488 $53,429
108 United States TN Mix Yes SOF-SMV BOC-PEG-RBV $71,528 -$20,309 $184,824 $62,517
109 United States TN Mix Yes SOF-DCV BOC-PEG-RBV $63,723 -$19,610 $198,896 $64,110
110 United States TN Mix Yes SOF-LDV BOC-PEG-RBV $11,927 -$16,585 $250,176 $73,418
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111 Younossi et al, 201537 United States TN Noncirrhosis No SOF-PEG-RBV No treatment -$8022 -$17,148 $368,098 $105,098
112 United States TN Noncirrhosis Yes SOF-LDV BOC-PEG-RBV -$28,897 -$31,259 $337,115 $124,453
113 United States TN Cirrhosis No SOF-PEG-RBV No treatment -$6535 -$12,461 $515,467 $110,467
114 United States TN Cirrhosis No SMV-PEG-RBV No treatment -$1248 -$3215 $374,805 $69,805
115 United States TN Cirrhosis No SOF-RBV No treatment $38,334 -$5215 $320,932 $72,932
116 United States TN Cirrhosis No SOF-SMV No treatment $25,382 -$18,333 $700,181 $159,181
117 United States TN Cirrhosis No SOF-LDV No treatment -$11,582 -$18,048 $679,752 $154,752
118 United States TN Cirrhosis Yes SOF-PEG-RBV BOC-PEG-RBV -$6283 -$25,483 $274,364 $95,254
119 United States TN Cirrhosis Yes SMV-PEG-RBV BOC-PEG-RBV $59,232 $35,232 $82,559 $41,942
120 United States TN Cirrhosis Yes SOF-RBV BOC-PEG-RBV -$355,253 $1,000,000a $0a $0a
121 United States TN Cirrhosis Yes SOF-SMV BOC-PEG-RBV $59,744 -$30,869 $411,402 $125,973
122 United States TN Noncirrhosis No SMV-PEG-RBV No treatment -$6561 -$9193 $308,960 $80,960
123 United States TN Cirrhosis Yes SOF-LDV BOC-PEG-RBV -$17,220 -$31,077 $487,422 $151,752
124 United States TE Mix No SOF-PEG-RBV No treatment -$4284 -$13,586 $353,052 $95,052
125 United States TE Mix No SMV-PEG-RBV No treatment $9318 $6348 $249,177 $47,177
126 United States TE Mix No SOF-RBV No treatment $25,234 -$17,119 $358,653 $103,653
127 United States TE Mix No SOF-SMV No treatment $13,003 -$20,663 $466,634 $129,634
128 United States TE Mix No SOF-LDV No treatment -$5907 -$16,206 $449,290 $114,290
129 United States TE Mix Yes SOF-PEG-RBV BOC-PEG-RBV -$17,169 -$41,411 $260,722 $109,895
130 United States TE Mix Yes SMV-PEG-RBV BOC-PEG-RBV $29,949 $15,995 $119,534 $43,113
131 United States TE Mix Yes SOF-RBV BOC-PEG-RBV $60,835 -$51,665 $213,398 $97,482
132 United States TE Mix Yes SOF-SMV BOC-PEG-RBV $21,278 -$42,460 $341,552 $128,018
133 United States TN Noncirrhosis No SOF-RBV No treatment $46,864 -$12,152 $265,239 $82,239
134 United States TE Mix Yes SOF-LDV BOC-PEG-RBV -$14,622 -$34,224 $384,950 $131,552
135 United States TE Mix Yes SOF-RBV No treatment $25,234 -$17,119 $358,653 $103,653
136 United States TE Mix Yes SOF-PEG-RBV No treatment -$4284 -$13,586 $353,052 $95,052
137 United States TE Mix Yes SOF-LDV No treatment -$6449 -$21,365 $471,428 $132,428
138 United States TN Noncirrhosis No SOF-SMV No treatment $10,758 -$19,648 $414,157 $118,157
139 United States TN Noncirrhosis No SOF-LDV No treatment -$16,736 -$17,742 $410,872 $112,872
140 United States TN Noncirrhosis Yes SOF-PEG-RBV BOC-PEG-RBV -$8614 -$34,701 $227,181 $95,356
141 United States TN Noncirrhosis Yes SMV-PEG-RBV BOC-PEG-RBV -$3135 -$13,661 $161,511 $68,903
142 United States TN Noncirrhosis Yes SOF-RBV BOC-PEG-RBV $824,450 -$75,550 $65,598 $51,463
143 United States TN Noncirrhosis Yes SOF-SMV BOC-PEG-RBV $36,013 -$35,987 $246,271 $95,817
144 Athanasakis et al, 201538 Greece TN Mix Yes BOC-PEG-RBV PEG-RBV $13,691 $55,509 $98,707 $11,707
145 Greece TE Mix Yes BOC-PEG-RBV PEG-RBV $14,803 $35,959 $140,051 $15,051
146 Pfeil et al, 201514 Switzerland TN Mix Yes BOC-PEG-RBV PEG-RBV $25,748 $76,382 $74,171 $14,171
147 Switzerland TN Mix Yes TEL-PEG-RBV PEG-RBV $24,598 $58,187 $93,451 $13,451
148 Switzerland TN Mix Yes SOF-PEG-RBV BOC-PEG-RBV $14,543 $13,700 $160,953 $43,412
149 Switzerland TN Mix Yes SOF-PEG-RBV TEL-PEG-RBV $11,240 $9,977 $138,973 $50,568
150 Switzerland TN Mix No SOF-RBV No treatment $92,190 $41,348 $130,382 $10,382
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Supplementary Table 3. Continued
Number Study Country
Treatment
history
Fibrosis
stage
IFN
tolerance
Primary
intervention Comparator
Reported
ICER
ICER at
$60,000
Threshold
drug price
($100,000 ICER)
Threshold
drug price
($0 ICER)
151 Zhang et al, 201515 United States TN Noncirrhosis Yes SOF-LDV TEL-PEG-RBV -$1224 -$22,450 $437,725 $98,651
152 United States TN Cirrhosis Yes SOF-PEG-RBV TEL-PEG-RBV $13,016 -$24,484 $218,376 $63,893
153 United States TN Noncirrhosis Yes SOF-SMV TEL-PEG-RBV $35,268 -$21,011 $304,048 $66,071
154 United States TN Noncirrhosis Yes Viekira Pak TEL-PEG-RBV -$7021 -$19,908 $525,201 $110,140
155 United States TN Noncirrhosis Yes SOF-PEG-RBV TEL-PEG-RBV $2411 -$17,075 $374,114 $76,831
156 United States TN Cirrhosis Yes SOF-LDV TEL-PEG-RBV -$5204 -$17,653 $702,679 $124,581
157 United States TN Cirrhosis Yes SOF-SMV TEL-PEG-RBV $65,184 -$16,770 $421,962 $71,663
158 United States TN Cirrhosis Yes Viekira Pak TEL-PEG-RBV $25,227 -$14,729 $436,136 $69,511
159 Westerhout
et al, 201539
United Kingdom TN Mix Yes BOC-PEG-RBV PEG-RBV $26,919 $54,143 $102,142 $10,242
160 United Kingdom TN Mix Yes TEL-PEG-RBV PEG-RBV $24,148 $49,546 $108,789 $12,089
161 United Kingdom TN Mix Yes SMV-PEG-RBV BOC-PEG-RBV $11,713 $1,000,000a $0a $0a
162 United Kingdom TN Mix Yes SMV-PEG-RBV TEL-PEG-RBV $8959 $1,000,000a $0a $0a
163 United Kingdom TE Mix Yes BOC-PEG-RBV PEG-RBV $22,514 $36,137 $145,385 $11,685
164 United Kingdom TE Mix Yes TEL-PEG-RBV PEG-RBV $14,382 $31,227 $160,271 $14,471
165 United Kingdom TE Mix Yes SMV-PEG-RBV BOC-PEG-RBV -$72,693 $1,000,000a $0a $0a
166 United Kingdom TE Mix Yes SMV-PEG-RBV TEL-PEG-RBV -$64,056 $1,000,000a $0a $0a
167 Odhiambo et al, 201340 Hungary TN Mix Yes BOC-PEG-RBV PEG-RBV $28,621 $90,835 $65,407 $6407
168 Hungary TE Mix Yes BOC-PEG-RBV PEG-RBV $21,850 $45,662 $121,402 $8402
169 Gimeno-Ballester
et al, 201541
Spain TN Noncirrhosis Yes SMV-DCV BOC-PEG-RBV $37,923 $20,460 $183,082 $11,252
170 Spain TN Noncirrhosis Yes SMV-DCV TEL-PEG-RBV $31,615 $12,746 $219,639 $10,203
NOTE. The threshold drug price of < $0 implies that the DAA will not be cost-saving at any price.
BOC, boceprevir; DCV, daclatasvir; LDV, ledipasvir; PEG, peginterferon; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir; TE, treatment-experienced patients; TEL, telaprevir; TN, treatment-naive patients; Viekira Pak is a
combination of four medications: ombitasvir, paritaprevir, ritonavir and dasabuvir,
aQALYs of primary intervention scenario were less than that of comparator scenario, and no drug price could make the primary intervention cost-effective or cost-saving. Therefore, our calculations and plotting, we assigned
ICER of $1,000,000 and threshold DAA prices to $0.
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Supplementary Table 4. Summary of Studies and ICERs
by Country
Country
Number of
ICERs
Number of
studies
United States 110 10
United Kingdom 17 3
The Netherlands 8 1
Switzerland 5 1
Spain 2 1
Singapore 7 1
Portugal 2 1
Italy 13 3
Hungary 2 1
Greece 2 1
Australia 2 1
Total 170 24
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